Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLG) EBITDA (2016 - 2017)

Bone Biologics has reported EBITDA over the past 2 years, most recently at -$1.3 million for Q4 2017.

  • Quarterly EBITDA rose 57.92% to -$1.3 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2017, up 87.13% year-over-year, with the annual reading at -$3.2 million for FY2025, 23.33% up from the prior year.
  • EBITDA was -$1.3 million for Q4 2017 at Bone Biologics, down from -$1.1 million in the prior quarter.
  • Over five years, EBITDA peaked at $2.0 million in Q2 2017 and troughed at -$9.1 million in Q1 2016.